-
公开(公告)号:US20240325348A1
公开(公告)日:2024-10-03
申请号:US18744247
申请日:2024-06-14
IPC分类号: A61K31/353 , A23L29/00 , A23L29/30 , A61K31/7048
CPC分类号: A61K31/353 , A23L29/035 , A23L29/30 , A61K31/7048
摘要: The present application provides a method for improvement in physical activity efficiency, a method for reducing fatigue, and a method for improving dynamic/kinetic visual acuity, comprising administering a composition comprising a kaempferol analog to a subject in need thereof.
-
公开(公告)号:USD1041321S1
公开(公告)日:2024-09-10
申请号:US35516618
申请日:2022-03-15
设计人: Mutsumi Ajichi
摘要: The file of this patent contains at least one figure executed in color. Copies of this patent with color figures will be provided by the United States Patent and Trademark Office upon request and payment of the necessary fee.
Fig. 1.1 is a front, top, and right side perspective view of a packaging bag showing my new design;
Fig. 1.2 is a front view thereof;
Fig. 1.3 is a rear view thereof; and
Fig. 1.4 is a front, bottom, and left side perspective view thereof, and showing the packaging bag in an expanded configuration.
The dash-dash broken lines and the part painted in dark gray form no part of the claimed design. The dot-dash broken lines show boundaries and form no part of the claimed design. The orange crescent-shaped area is translucent.-
公开(公告)号:US20240287051A1
公开(公告)日:2024-08-29
申请号:US18568772
申请日:2022-06-10
发明人: Prabhubas BODHURI , Hem Raj KHATRI , Ian SCOTT , Michael READER , David Charles LATHBURY , Nipun DAVAR , Matthew JOHNSON
IPC分类号: C07D405/14 , C07C67/10 , C07C217/70 , C07C271/16 , C07C313/06 , C07D209/46 , C07D405/12 , C07F5/02 , C12N9/10
CPC分类号: C07D405/14 , C07C67/10 , C07C217/70 , C07C271/16 , C07C313/06 , C07D209/46 , C07D405/12 , C07F5/025 , C12N9/1096 , C12Y206/01029
摘要: The present disclosure relates generally to methods for the preparation of Compound (I).
-
公开(公告)号:US20240277702A1
公开(公告)日:2024-08-22
申请号:US18541083
申请日:2023-12-15
发明人: Tetsuya SATO , Takuya MINOWA , Yusuke HOSHIKA , Hidekazu TOYOFUKU
IPC分类号: A61K31/496 , A61K9/00 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/20 , A61K47/24 , A61K47/26 , A61K47/34
CPC分类号: A61K31/496 , A61K9/0019 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/20 , A61K47/24 , A61K47/26 , A61K47/34
摘要: An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week.
-
公开(公告)号:US12016927B2
公开(公告)日:2024-06-25
申请号:US18148860
申请日:2022-12-30
发明人: Daiki Kaneko , Takakuni Matsuda , Yusuke Hoshika
CPC分类号: A61K47/32 , A61K9/0019 , A61K9/06 , A61K31/496 , A61K47/10 , A61K47/38 , A61K9/0024
摘要: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s−1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s−1, as measured.
-
公开(公告)号:US20240165030A1
公开(公告)日:2024-05-23
申请号:US18427459
申请日:2024-01-30
发明人: Syed Asfar Mateen , Praveen Kumar Mididoddi , Shailly Mehrotra , Susan Elizabeth Shoaf , Salin Gupta , Kai Suzuki , Masahiro Hasegawa
IPC分类号: A61K9/16 , A61K31/403
CPC分类号: A61K9/167 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K31/403
摘要: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
-
7.
公开(公告)号:US20240156811A1
公开(公告)日:2024-05-16
申请号:US18455757
申请日:2023-08-25
发明人: Tsuyoshi HIROSE , Kenji MAEDA , Tetsuro KIKUCHI , Masafumi TODA
IPC分类号: A61K31/496 , A61K9/20 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/5513 , A61K45/06
CPC分类号: A61K31/496 , A61K9/20 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/5513 , A61K45/06
摘要: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (1) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
-
公开(公告)号:US20240140910A1
公开(公告)日:2024-05-02
申请号:US17769250
申请日:2020-10-15
发明人: Rei Otsuka , Kimiyoshi Annaka , Hikaru Mitani
IPC分类号: C07D209/52
CPC分类号: C07D209/52
摘要: The present invention addresses the problem of finding a method for reliably producing (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, wherein crystalline polymorphs can be controlled with industrially easy operations. Provided is a method for producing a crystalline form of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride, the method comprising: step (a) for heating and dissolving (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride in a solvent including an alcohol-based solvent; step (b) for cooling the dissolved product of step (a) to a temperature, at which crystals of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride precipitate, to nucleate the crystals; step (c) for heating a mixture containing the crystals obtained by nucleation to a temperature at which only a specific crystalline form selectively remains; and step (d) for cooling the mixture heated in step (c) to obtain the crystalline form.
-
公开(公告)号:US20240139177A1
公开(公告)日:2024-05-02
申请号:US18396036
申请日:2023-12-26
摘要: Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 ?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension.
-
公开(公告)号:US11963971B2
公开(公告)日:2024-04-23
申请号:US18309440
申请日:2023-04-28
发明人: Aram Oganesian , Nipun Davar , Jim Hwaicher Kou
IPC分类号: A61K31/706 , A61K9/00 , A61K9/20 , A61K9/48 , A61K31/20 , A61K31/7016 , A61K31/717
CPC分类号: A61K31/706 , A61K9/0056 , A61K9/20 , A61K9/4891 , A61K31/20 , A61K31/7016 , A61K31/717
摘要: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
-
-
-
-
-
-
-
-
-